Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial | Zendy

Naomi Kiyota | Zendy; Bruce Robinson | Zendy; Manisha H. Shah | Zendy; Ana O. Hoff | Zendy; Matthew H. Taylor | Zendy; Li Di | Zendy; Corina E. Dutcus | Zendy; Eun Kyung Lee | Zendy; SungBae Kim | Zendy; Makoto Tahara | Zendy

Open Access

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Author(s) -

Naomi Kiyota,

Bruce Robinson,

Manisha H. Shah,

Ana O. Hoff,

Matthew H. Taylor,

Li Di,

Corina E. Dutcus,

Eun Kyung Lee,

SungBae Kim,

Makoto Tahara

Publication year - 2017

Publication title -

thyroid

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.918

H-Index - 142

eISSN - 1557-9077

pISSN - 1050-7256

DOI - 10.1089/thy.2016.0549

Subject(s) - lenvatinib , refractory (planetary science) , thyroid cancer , medicine , safety profile , oncology , thyroid , clinical trial , adverse effect , biology , astrobiology

While there is a clear consensus for defining radioiodine-refractory differentiated thyroid cancer (RR-DTC), it is unknown whether these criteria are equally valid for determining when radioiodine (RAI) therapy is no longer beneficial and systemic treatment should be considered. Lenvatinib, a multikinase inhibitor, significantly prolonged progression-free survival (PFS) compared to placebo in a Phase 3 trial in RR-DTC (SELECT; hazard ratio [HR]: 0.21 [99% confidence interval (CI) 0.14-0.31]; p < 0.001). This sub-analysis compared clinical outcomes of lenvatinib-treated patients in SELECT stratified by RR-DTC inclusion criteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research